What You Should Know:
– Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North.
- The round also included participation from Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100M since Ibex’s inception in 2016.
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Oncology Software: The Digital Backbone of Cancer Care
The complex and dynamic landscape of multimodal cancer care is boosting demand for oncology-specific technological innovations. The need for elevated cancer care is steadily climbing, compelling software developers to create increasingly integrated and sophisticated solutions. Oncology has always been at the forefront of digitization due to the substantial amount of data needed and generated for each patient during the treatment process. Today, advanced oncology software offers clinicians a
Read More
PicnicHealth Enters Oncology Real-World Data Market
What You Should Know:
PicnicHealth, a patient-centered health technology company, today announced its entry into the real-world data market for oncology.Drawing from its success working with chronic disease patients to create robust datasets, the company aims to advance oncology research using a similar model by working directly with people living with cancer to collect and structure their medical records data. PicnicHealth is actively exploring partnerships to develop new patient
Read More
Finance: Elevation Oncology Announces Pricing of $50M IPO
What You Should Know:
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000
Read More
Why AI-Driven Cancer Screening Will Soon Become Standard of Care
Healthcare delivery is undergoing a dramatic transformation as AI technologies begin to take hold in the care setting. The technology is revolutionizing radiology, particularly in ED triage, early disease detection, and now in cancer imaging and reporting. These fields are particularly suited to improvements using AI, given their antiquated workflows and resistance to change over the decades. But how – specifically – is AI transforming this industry for good?
Using AI for advanced
Read More
Roundups: HealthJoy Expands Partnership With Teladoc Health, Oura, Other Strategic Partnerships
Roundup summary of recent digital health strategic partnerships:
HealthJoy, Teladoc Health Launch Virtual Primary Care
HealthJoy, a benefits navigation platform that amplifies employer benefit strategies expands its partnership with Teladoc Health to introduce virtual primary care. HealthJoy Virtual Primary Care, powered by Teladoc Health, provides a fully integrated primary care experience that supports members throughout their entire healthcare journey. The solution will further
Read More
Sanofi & Flatiron Health Partner to Redesign Clinical Trial Experience for Sponsors
What You Should Know:
Flatiron Health announced a new partnership today with Sanofi in their pursuit to redesign the clinical trial experience for sponsors, sites, and patients in the therapeutic area of oncology. The multi-study partnership between Sanofi and Flatiron will focus on improving clinical trial data acquisition, delivery, and quality through site-facing technology that digitally transfers data captured in the electronic health record (EHR) directly into the electronic data
Read More
Quest Diagnostics Acquires Haystack Oncology for $300M in Cash
What You Should Know:
Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Report: Prior Authorization for Biomarker Testing Leads to Treatment Delays For Cancer Patients
What You Should Know:
Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. According to a new survey released by CancerCare, a leading national cancer support organization, biomarker testing helped doctors tailor therapy for nearly all the respondent patients (93%) whose cancers were tested over the past three years. Two in 10 cancer patients (20%) surveyed were able to avoid unnecessary chemotherapy and/or radiation and 10% became eligible for
Read More
Exec Hires: COTA Appoints First Chief Commercial Officer
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, today announced the appointment of Sandy Leonard as its first Chief Commercial Officer.
- As CCO, Sandy will drive COTA’s life sciences growth strategy, prioritizing customer success and experience. More specifically, she will lead a team that is laser-focused on ensuring that pharmaceutical partners have the data assets, analytics, services, and support they need to develop life-saving
Read More
